The Latest Breaking News from ResMed

ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Australians should take sleep seriously as a survey marking World Sleep Day sheds light on the impact of financial pressures, experts say.

For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of the pandemic.

Upgrades

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 18.75%. Currently, ResMed has a market capitalization of $30.88 billion.

ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all regular shares that are available for trading.

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81 billion.

ResMed Inc (NYSE:RMD) has agreed to acquire privately-held MEDIFOX DAN, a Germany-based provider of out-of-hospital software solutions, from Hg, a software and services investor.  MEDIFOX DAN's clinical, financial, and operational solutions are similar to ResMed's U.S. SaaS brands, MatrixCare and Brightree. MEDIFOX DAN's German customer base is complementary to the customers of ResMed's U.S.-based…